Clearmind Medicine Inc. Accelerates Mission To Make History With Psychedelic-Based Therapeutics ($CMND)
Weakness in Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND) stock is less a trend than it is an opportunity. In fact, the decline in value over the past two weeks may be well overdone, noting that a series of milestones reached, patents earned, and valuable partnerships ideally position CMND to have its best year in 2023. Driving that proposition is Clearmind Medicine nearing its goal of delivering a first-to-market psychedelic-based treatment to market, with its lead candidate, MEAI, targeting a









